Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03081455 · ClinicalTrials.gov registry record
Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 145
- Enrollment target
NCT03081455: Completed study, sponsored by Myriad Genetic Laboratories.
NCT03081455 is a clinical trial that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03081455 has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
A prospective, non-interventional study to evaluate the impact of a process engineering intervention on screening and testing outcomes for common hereditary cancer syndromes in community-based OB/GYN settings.
Interventions
- DIAGNOSTIC_TEST Diagnostic Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2017-08-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03081455
The ClinicalTrials.gov registry entry for NCT03081455 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic Test is the first listed.
NCT03081455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03081455 about?
NCT03081455 is a clinical study titled "Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes". A prospective, non-interventional study to evaluate the impact of a process engineering intervention on screening and testing outcomes for common hereditary cancer syndromes in community-based OB/GYN settings.
What is the current status of trial NCT03081455?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2017-02-13. Estimated completion is 2017-08-04.
What interventions are being tested in trial NCT03081455?
The interventions under investigation include: Diagnostic Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03081455?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.